Breast cancer (Tokyo, Japan)最新文献

{"title":"Immediate breast reconstruction surgery for breast cancer: current status and future directions.","authors":"Tadahiko Shien, Hiroko Nogi, Akiko Ogiya, Makoto Ishitobi, Chikako Yamauchi, Ayaka Shimo, Kazutaka Narui, Naomi Nagura, Hirohito Seki, Kaori Terata, Miho Saiga, Tatsuya Uchida, Shinsuke Sasada, Teruhisa Sakurai, Naoki Niikura, Hiroki Mori","doi":"10.1007/s12282-025-01723-5","DOIUrl":"10.1007/s12282-025-01723-5","url":null,"abstract":"<p><strong>Background: </strong>Immediate breast reconstruction (IBR) has become increasingly recognized in Japan as an important component of breast cancer care, improving patients' quality of life after mastectomy. While the adoption of IBR is growing, the reconstruction rate in Japan remains lower than in Western countries. To clarify the current practice and challenges, the Japanese Breast Cancer Society (JBCS) conducted a nationwide survey.</p><p><strong>Methods: </strong>We conducted a comprehensive web-based questionnaire survey among all JBCS-certified institutions between December 2020 and February 2021. The survey assessed institutional capabilities, surgical techniques, decision-making criteria for BR, and the integration of adjuvant therapy.</p><p><strong>Results: </strong>A total of 429 institutions responded, with 72.5% offering BR and 61.7% capable of providing immediate reconstruction. Nipple-sparing mastectomy (NSM) was performed at 73.7% of institutions offering reconstruction. Multidisciplinary conferences with plastic surgeons were held at 70.5% of institutions. Approximately 30% of institutions discontinued IBR if sentinel lymph node metastases were detected intraoperatively, and 62.8% avoided recommending IBR for patients likely to require postoperative radiation therapy. In 94% of institutions, BR did not cause delays in the administration of adjuvant chemotherapy. However, 15% of institutions modified their radiation therapy approach in reconstructed patients. Additionally, 27% of physicians still believed that BR could negatively affect prognosis.</p><p><strong>Conclusions: </strong>The survey confirmed that IBR is widely performed and feasible in Japan. However, institutional differences, limited access to plastic surgeons, and persistent misconceptions remain significant barriers. Strengthening multidisciplinary collaboration and establishing standardized guidelines will help improve BR rates and patient outcomes in Japan.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"630-637"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.","authors":"Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Ken-Ichi Watanabe, Masami Tsukabe, Fumie Fujisawa, Shigenori E Nagai, Nobuhiro Shibata, Chiya Oshiro, Hiroko Bando, Nobuyuki Tsunoda, Kazuhiko Yamagami, Kei Koizumi, Masahiro Takada, Naoko Toriguchi, Nobuyuki Sekine, Tsutomu Kawaguchi, Shigehira Saji, Yasuaki Sagara, Satoshi Morita, Norikazu Masuda","doi":"10.1007/s12282-025-01713-7","DOIUrl":"10.1007/s12282-025-01713-7","url":null,"abstract":"<p><strong>Background: </strong>A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is a current standard first-/second-line treatment for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (AMBC). We aimed to provide real-world evidence regarding CDK4/6i therapy in this population.</p><p><strong>Methods: </strong>In this multicenter observational study, data from patients who had started CDK4/6i therapy between January 1, 2019, and December 31, 2021, as first-/second-line treatment for AMBC were used; real-world progression-free survival (rwPFS), chemotherapy-free survival, and overall survival were analyzed using the Kaplan-Meier method. Additionally, data were analyzed by separating patients with treatment-free interval (TFI) < 12 months (deemed resistant to ET) from the first-line treatment group (hereafter, the exclusive first-line treatment group).</p><p><strong>Results: </strong>Data from 745 patients were analyzed. Compared with palbociclib, abemaciclib was used in younger patients and those with expected poor prognosis. Median rwPFS was 36.8, 17.8, and 31.4 months in patients with de novo stage IV disease, TFI < 12 months, and TFI ≥ 12 months, respectively, in the first-line treatment group, and 17.4 months in the second-line treatment group. In the exclusive first-line treatment group, median rwPFS of the subsequent treatment after initial CDK4/6i plus ET was < 7 months, regardless of the type of subsequent treatment; prognosis was especially poor in those who were switched to chemotherapy.</p><p><strong>Conclusions: </strong>The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"841-856"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of transcriptome profiles of radiotherapy beams on MCF-7 breast cancer xenografts.","authors":"Tuğba Kul Köprülü, Serhat Aras, Burçin Erkal Çam, Altan Kara","doi":"10.1007/s12282-025-01735-1","DOIUrl":"https://doi.org/10.1007/s12282-025-01735-1","url":null,"abstract":"<p><p>The objective of this study was to investigate the acute radiobiological mechanisms underlying Flattening Filter (FF) and Flattening Filter Free (FFF) radiotherapy-induced inhibition of breast cancer (BCa) by detecting changes in gene expression levels. The study involved thirty-six adult nude mice models that were randomly divided into five groups: control (G1), breast cancer (BCa) (G2), FF-400 (G3), FFF-1120 (G4), and FFF-1820 (G5). The control group had no radiation or treatment, while the BCa group had a cancer model but no radiation. The BCa models were subjected to a single dose of 20 Gy of radiotherapy at varying dose rates: 400, 1120, and 1820 MU/min (G3, G4, and G5, respectively). Twenty days after implantation of the MCF-7 cancer cell line, nude mice were irradiated and sacrificed 48 h later for genetic analysis. A transcriptome library was created by extracting RNA from tissue samples. In the differentially expressed genes (DEG) analysis, a total of 1565 genes were found to be significantly altered in the G2 vs. G1 groups. When radiotherapy groups (G3, G4, and G5) were analyzed, 334 DEGs (231 down, 103 up) were identified in G3 vs G2 data, 167 DEGs (103 down, 64 up) in G4 vs G2 data, and 187 DEGs (116 down, 71 up) in G5 vs G2 data. Gene Ontology molecular function analysis revealed significant differences between groups G3 and G2, with an emphasis on protein binding, glutamate receptor activity, and interleukin-8 receptor activation. Similar features were observed when comparing groups G5 and G2. The analysis showed significant differences in the expression of the key ERAD pathway genes Ufd1 and Cav1 between the BCa and radiotherapy groups. It was concluded that the FFF beam significantly alters the processes underlying the ERAD pathway and glutamate receptor activation compared to the FF beam.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.","authors":"Aya Imai, Ryo Tsunashima, Yu Hidaka, Sae Kitano, Chikage Kato, Akira Watanabe, Midori Morita, Koichi Sakaguchi, Yoshiaki Sota, Masahiko Suzuki, Takayuki Kinoshita, Seiichi Imanishi, Masahiro Oikawa, Yoshihiko Kamada, Ken-Ichi Ito, Takaaki Oba, Shin Takayama, Fumine Tsukamoto, Mina Takahashi, Yutaka Hatanaka, Naoto T Ueno, Kenzo Shimazu, Satoshi Morita, Yasuto Naoi","doi":"10.1007/s12282-025-01734-2","DOIUrl":"https://doi.org/10.1007/s12282-025-01734-2","url":null,"abstract":"<p><strong>Background: </strong>In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative recurrence prediction, has been commercially available since 2013. Since 2021, five validation studies evaluating the predictive performance 95GC have been published. This study presents an integrated analysis of these studies to validate the prognostic utility of 95GC further.</p><p><strong>Methods: </strong>The integrated analysis included 719 real-world cases of luminal-type node-negative breast cancer patients who underwent adjuvant hormone therapy alone without extended endocrine treatment. In addition, an expanded cohort incorporating 294 cases from Western patients within the GEO public database was analyzed, resulting in a total of 1013 cases.</p><p><strong>Results: </strong>Among the 719 real-world cases, 550 (76.5%) were classified into the 95GC Low-risk group, demonstrating a significantly superior prognosis compared to the High-risk group (P < 1.00e-12). The 5-year distant recurrence-free survival (DRFS) rate in the Low-risk group was approximately 98%, with consistent findings observed in the expanded cohort. Furthermore, an analysis of 754 CEL files using 21GC (a proxy for Oncotype DX®) identified 318 cases (42.2%) as the 21GC intermediate risk. 95GC successfully stratified these cases into two prognostically distinct subgroups.</p><p><strong>Conclusions: </strong>These findings underscore the clinical utility of 95GC in safely omitting chemotherapy for Low-risk patients with good prognosis and in further stratifying the 21GC Intermediate-risk cases, thereby contributing to personalized treatment strategies.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.","authors":"Meiling Huang, Jian Zhang, Changjiao Yan, Rui Ling, Ting Wang","doi":"10.1007/s12282-025-01737-z","DOIUrl":"https://doi.org/10.1007/s12282-025-01737-z","url":null,"abstract":"<p><strong>Background: </strong>Kruppel-like factor 13 (KLF13) influences both immune system disorders and cancer progression, whereas the effects of KLF13 on the immune escape and breast cancer remain incompletely understood.</p><p><strong>Research design and methods: </strong>KLF13 expression was assessed in breast cancer tumor tissues. The roles of KLF13 in cell proliferation, migration, and immune evasion were assessed. RNA sequencing was used to identify the differentially expressed genes and signaling. Chip-seq and luciferase assays were performed to validate binding of KLF13 to its downstream genes. In vivo studies were conducted to confirm the function of KLF13. The mechanisms were elucidated using recovery assays.</p><p><strong>Results: </strong>KLF13 levels were higher in breast cancer tissue. Silencing KLF13 markedly diminished cell proliferation, migration, mammosphere formation, and immune evasion by suppressing the levels of HTRA1 and the Hedgehog signaling pathway. KLF13 overexpression potentiated breast cancer aggressiveness and enhanced immune evasion. Inhibiting KLF13 delayed development of cancer xenografts, as well as curtailing tumor growth, which were reversed by co-expression of HTRA1. Clinical relevance results suggested a positive correlation between KLF13, HTRA1 and density of CD8T cells in human breast cancer patients.</p><p><strong>Conclusions: </strong>KLF13 can serve as a tumor promoter in breast cancer by influencing HTRA1 and the Hedgehog signaling pathway.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.","authors":"Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Ken-Ichi Watanabe, Masami Tsukabe, Fumie Fujisawa, Shigenori E Nagai, Nobuhiro Shibata, Chiya Oshiro, Hiroko Bando, Nobuyuki Tsunoda, Kazuhiko Yamagami, Kei Koizumi, Masahiro Takada, Naoko Toriguchi, Nobuyuki Sekine, Tsutomu Kawaguchi, Shigehira Saji, Yasuaki Sagara, Satoshi Morita, Norikazu Masuda","doi":"10.1007/s12282-025-01736-0","DOIUrl":"https://doi.org/10.1007/s12282-025-01736-0","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging roles of KIR2DL4 in cancer immunotherapy.","authors":"Weimiao Li, Guoxu Zheng, Shuqun Zhang","doi":"10.1007/s12282-025-01738-y","DOIUrl":"https://doi.org/10.1007/s12282-025-01738-y","url":null,"abstract":"<p><p>Killer-cell immunoglobulin-like receptor 2DL4 (KIR2DL4), a member of the killer cell immunoglobulin-like receptors (KIRs) family, plays an important role in the regulation of the immune system, which is expressed primarily on natural killer (NK) cells. Human leucocyte antigen-G (HLA-G), a non-classical major histocompatibility complex (MHC) class I molecule, is the only known ligand of KIR2DL4. Accumulating evidence has shown that KIR2DL4 has emerged as a potential target for enhancing the antitumor immune response. Elevated expression of KIR2DL4 has been observed in certain tumor types, including melanoma, lung cancer, and ovarian cancer, indicating its role in tumor evasion. Our previous study had shown that blockade of KIR2DL4 interaction in NK cells can re-sensitize breast cancer to trastuzumab treatment, which indicated that KIR2DL4 was a pivotal immune checkpoint of NK cells. Currently, there are several therapeutic approaches targeting KIR in cancer immunotherapy. However, there are no efficient cancer immunotherapy strategy targeting KIR2DL4. In this review, we aim to summarize and discuss the potential role of KIR2DL4 as a target for cancer immunotherapy. A better understanding of KIR2DL4 might be helpful to develop effective KIR2DL4-targeted therapies, which could provide new treatment options for cancer patients.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marital status as an independent prognostic factor in male breast cancer: a SEER-based cohort study.","authors":"Ahmet Necati Sanli, Bilal Turan, Deniz Esin Tekcan Sanli, Fatih Aydogan, M Kadri Altundag","doi":"10.1007/s12282-025-01733-3","DOIUrl":"https://doi.org/10.1007/s12282-025-01733-3","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) is a rare malignancy, and research on its prognostic factors remains limited. Marital status has been identified as a prognostic determinant in various cancers; however, the impact of marital status on MBC survival outcomes remains understudied. This study examines the relationship between marital status and survival in MBC patients using a large, population-based cohort.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the Surveillance, Epidemiology, and End Results (SEER) 17 Registries database (2010-2021). MBC patients (n = 5,994) were categorized into four marital status groups: married, unmarried, divorced, and widowed. Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models were used to assess overall survival (OS) and disease-specific survival (DSS).</p><p><strong>Results: </strong>Significant differences in OS and DSS were observed among marital status groups (p < 0.001). Widowed patients had the poorest survival outcomes, with a 2.59 times higher increased mortality risk (HR = 2.594, 95% CI: 2.246-2.996, p < 0.001) compared to married individuals in univariate analysis. This association remained significant in multivariate analysis, with widowed patients demonstrating a 1.72 times higher mortality risk (HR = 1.724, 95% CI: 1.421-2.092, p < 0.001) after adjustment for clinicopathological and demographic variables. Unmarried and divorced patients also had poorer survival outcomes than married patients, albeit with lower hazard ratios.</p><p><strong>Conclusions: </strong>Marital status is an independent prognostic factor in MBC, with widowed patients experiencing the poorest outcomes. These findings underscore the important role of social and psychological support in cancer prognosis. Integrating psychosocial support programs and patient-centered care approaches into oncological practice can help reduce survival disparities.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases.","authors":"Makoto Ishitobi, Atsushi Yoshida, Yuri Kimura, Yasuaki Sagara, Yuka Ono, Koji Takada, Yuko Takahashi, Takahiro Tsukioki, Mao Kimoto, Tomo Osako, Takehiko Sakai","doi":"10.1007/s12282-025-01732-4","DOIUrl":"https://doi.org/10.1007/s12282-025-01732-4","url":null,"abstract":"<p><strong>Background: </strong>There is no consensus regarding the optimal margin status among patients with breast cancer treated with neoadjuvant chemotherapy (NAC), breast-conserving surgery, and radiotherapy (breast-conserving treatment [BCT]).</p><p><strong>Methods: </strong>In total, 1813 patients with newly diagnosed stage 1-3 breast cancer who underwent BCT after NAC were evaluated to determine the impact of margin status on ipsilateral breast tumor recurrence (IBTR).</p><p><strong>Results: </strong>During a median follow-up period of 8.0 years (range 0.1-17.0 years), the 8-year IBTR-free survival rate was 95.9%. Patients with positive margins had significantly worse IBTR-free survival than those with negative margins (8-year IBTR-free survival rate: 87.6% vs. 96.2%, p = 0.010). Multivariate analysis showed that margin status was significantly associated with IBTR-free survival (hazard ratio: 3.1; 95% confidence interval 1.3-7.2; p = 0.0081).</p><p><strong>Conclusions: </strong>This multicenter retrospective study demonstrated that margin status is significantly associated with IBTR-free survival in patients who received NAC and BCT, consistent with findings in upfront-surgery cases.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.","authors":"Yumiko Akita, Ravi Velaga, Madoka Iwase, Satoko Shimada, Toyone Kikumori, Dai Takeuchi, Yuko Takano, Takahiro Ichikawa, Tomoki Ebata, Norikazu Masuda","doi":"10.1007/s12282-025-01729-z","DOIUrl":"https://doi.org/10.1007/s12282-025-01729-z","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}